A pivotal phase III trial of edasalonexent in ambulatory patients with Duchenne Muscular Dystrophy

Trial Profile

A pivotal phase III trial of edasalonexent in ambulatory patients with Duchenne Muscular Dystrophy

Planning
Phase of Trial: Phase III

Latest Information Update: 30 Nov 2016

At a glance

  • Drugs Edasalonexent (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 30 Nov 2016 New trial record
    • 17 Nov 2016 According to a Catabasis Pharmaceuticals media release, this trial is anticipated to initiate in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top